Prospective Grant of Exclusive Patent License: Chimeric L1/L2 Protein and Virus-Like Particles Based Human Papillomavirus Vaccines, 23012-23013 [2017-10153]
Download as PDF
23012
Federal Register / Vol. 82, No. 96 / Friday, May 19, 2017 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Chimeric L1/L2 Protein and
Virus-Like Particles Based Human
Papillomavirus Vaccines
National Institutes of Health,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an exclusive patent license to
practice the inventions embodied in the
U.S. Patents and Patent Applications
listed in the Supplementary Information
section of this notice to PathoVax, LLC
located in Baltimore, MD.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before June 5, 2017 will be
considered.
SUMMARY:
Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
Kevin W. Chang, Ph.D., Senior
Technology Transfer Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702 Telephone: (240)-276–6910;
Facsimile: (240)-276–5504 Email:
changke@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Intellectual Property
United States Provisional Patent
Application No. 60/649,249 filed
February 1, 2005 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Crossneutralizing Antibodies’’ [HHS
Reference No. E–103–2005/0–US–01];
United States Provisional Patent
Application No. 60/697,655 filed July 7,
2005 and entitled, ‘‘Papillomavirus L2
N-terminal Peptides For The Induction
Of Broadly Cross-neutralizing
Antibodies’’ [HHS Reference No. E–
103–2005/1–US–01]; United States
Provisional Patent Application No. 60/
752,268 filed December 21, 2005 and
entitled, ‘‘Papillomavirus L2 N-terminal
Peptides For The Induction Of Broadly
VerDate Sep<11>2014
20:24 May 18, 2017
Jkt 241001
Cross-neutralizing Antibodies’’ [HHS
Reference No. E–103–2005/2–US–01];
International PCT Application No. PCT/
US2006/003601 filed February 1, 2006,
and entitled, ‘‘Papillomavirus L2 Nterminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies’’
[HHS Reference No. E–103–2005/3–
PCT–01]; United States Patent No.
8,404,244, issued March 26, 2013 and
entitled, ‘‘Papillomavirus L2 N-terminal
Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies’’ [HHS
Ref. No. E–103–2005/3–US–02]; United
States Patent No. 9,388,221 issued July
12, 2016 and entitled, ‘‘Papillomavirus
L2 N-terminal Peptides For The
Induction Of Broadly Cross-neutralizing
Antibodies’’ [HHS Ref. No. E–103–2005/
3–US–10]; Canadian Patent Application
No. 2,596,698 filed February 1, 2006
and entitled, ‘‘Papillomavirus L2 Nterminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies’’
[HHS Ref. No. E–103–2005/3–CA–03];
Australian Patent No. 2006210792
issued November 8, 2012 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Crossneutralizing Antibodies’’ [HHS Ref. No.
E–103–2005/3–AU–04]; Japanese Patent
No. 5224821 issued March 22, 2013 and
entitled, ‘‘Papillomavirus L2 N-terminal
Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies’’ [HHS
Ref. No. E–103–2005/3–JP–05];
Brazilian Patent Application No.
PI0607097–3 filed February 1, 2006 and
entitled, ‘‘Papillomavirus L2 N-terminal
Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies’’ [HHS
Ref. No. E–103–2005/3–BR–06]; Chinese
Patent No. 200680011079.1 issued
March 27, 2013 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Crossneutralizing Antibodies’’ [HHS Ref. No.
E–103–2005/3–CN–07]; Indian Patent
No. 263255 issued October 16, 2014 and
entitled, ‘‘Papillomavirus L2 N-terminal
Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies’’ [HHS
Ref. No. E–103–2005/3–IN–08];
European Patent No. 1853307 issued
December 14, 2016 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Crossneutralizing Antibodies’’ [HHS Ref. No.
E–103–2005/3–EP–09]; German Patent
No. 1853307 issued December 14, 2016
and entitled, ‘‘Papillomavirus L2 Nterminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies’’
[HHS Ref. No. E–103–2005/3–DE–11];
French Patent No. 1853307 issued
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
December 14, 2016 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Crossneutralizing Antibodies’’ [HHS Ref. No.
E–103–2005/3–FR–12]; and United
Kingdom Patent No. 1853307 issued
December 14, 2016 and entitled,
‘‘Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Crossneutralizing Antibodies’’ [HHS Ref. No.
E–103–2005/3–GB–13]. The patent
rights in these inventions have been
assigned and/or exclusively licensed to
the government of the United States of
America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of Licensed Patent Rights for the
following: ‘‘Use of Human
Papillomavirus Virus (HPV) L1/L2
chimeric proteins and Virus Like
Particles (VLPs) for the prevention and/
or treatment of cutaneous, mucosal HPV
infections and diseases.’’
The subject technologies are
papillomavirus L2 capsid protein based
vaccines against HPV. The L2 protein is
the minor papillomavirus capsid protein
for papillomaviruses. It is known that
antibodies to this protein can neutralize
homologous infection. Furthermore, L2
proteins can induce cross-neutralizing
antibodies. Specifically, epitopes at the
N-terminus of L2 shared by cutaneous
and mucosal types of papillomavirus
types and by types that infect divergent
species are broadly cross-neutralizing.
These epitopes at the N-terminus of L2
can be used to elicit cross-neutralizing
antibodies against different types of
HPV.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
E:\FR\FM\19MYN1.SGM
19MYN1
Federal Register / Vol. 82, No. 96 / Friday, May 19, 2017 / Notices
Dated: May 11, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–10153 Filed 5–18–17; 8:45 am]
Prospective Grant of Exclusive Patent
License: The Development of
Monospecific and Bispecific
Antibodies to GPC3 for the Treatment
of Human Liver Cancers
National Institutes of Health
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
ACTION:
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; NIAAA Fellowship Review.
Date: July 21, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, Terrace Level Conference Room,
5635 Fishers Lane, Bethesda, M.D 20892
Contact Person: Richard A. Rippe, Ph.D.,
Scientific Review Officer , Extramural Project
Review Branch, Office of Extramural
Activities, National Institute on Alcohol
Abuse and Alcoholism, 5635 Fishers Lane,
Room 2109, Rockville, MD 20852, 301–443–
8599, rippera@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards., National
Institutes of Health, HHS)
Dated: May 15, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–10113 Filed 5–18–17; 8:45 am]
BILLING CODE 4140–01–P
19:15 May 18, 2017
Jkt 241001
Notice.
The National Cancer Institute,
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an Exclusive Patent License to AbPro,
located in Woburn, Massachusetts, to
practice the inventions embodied in the
patent applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the NCI Technology
Transfer Center on or before June 5,
2017 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: David A. Lambertson, Ph.D.,
Senior Licensing and Patenting
Manager, NCI Technology Transfer
Center, 9609 Medical Center Drive, RM
1E530 MSC 9702, Bethesda, MD 20892–
9702 (for business mail), Rockville, MD
20850–9702, Telephone: (240)–276–
6467; Email: david.lambertson@nih.gov.
SUPPLEMENTARY INFORMATION: The
following represents the intellectual
property to be licensed under the
prospective agreement: U.S. Provisional
Patent Application 61/654,232 entitled
‘‘High-affinity Monoclonal Antibodies
To Glypican-3 And Use Thereof’’ [HHS
Ref. E–136–2012/0–US–01], PCT Patent
Application PCT/US2013/043633
entitled ‘‘High-affinity Monoclonal
Antibodies To Glypican-3 And Use
Thereof’’ [HHS Ref. E–136–2012/0–
PCT–02], Chinese Patent Application
201380039993.7 entitled ‘‘High-affinity
Monoclonal Antibodies To Glypican-3
And Use Thereof’’ [HHS Ref. E–136–
2012/0–CN–03], Japanese Patent
Application 2015–515243 entitled
‘‘High-affinity Monoclonal Antibodies
To Glypican-3 And Use Thereof’’ [HHS
Ref. E–136–2012/0–JP–04], South
Korean Patent Application 10–2014–
7037046 entitled ‘‘High-affinity
Monoclonal Antibodies To Glypican-3
And Use Thereof’’ [HHS Ref. E–136–
2012/0–KR–05], Singapore Patent
Application 11201407972R entitled
SUMMARY:
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
National Institutes of Health,
HHS.
National Institutes of Health
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
23013
‘‘High-affinity Monoclonal Antibodies
To Glypican-3 And Use Thereof’’ [HHS
Ref. E–136–2012/0–SG–06], and United
States Patent 9,409,994 entitled ‘‘Highaffinity Monoclonal Antibodies To
Glypican-3 And Use Thereof’’ [HHS Ref.
E–136–2012/0–US–07], and all
continuing U.S. and foreign patents/
patent applications for the technology
family, to AbPro. The patent rights in
these inventions have been assigned to
and/or exclusively licensed to the
Government of the United States of
America.
With respect to persons who have an
obligation to assign their right, title and
interest to the Government of the United
States of America, the patent rights in
these inventions have been assigned to
the Government of the United States of
America.
The prospective Exclusive Patent
License territory may be worldwide for
the following field of use:
The use of the YP7, YP8 and YP9.1 antiGPC3 monoclonal antibodies as monospecific
or bispecific antibodies for the treatment of
liver cancer. The licensed field of use
excludes any non-specified
immunoconjugates, including, but not
limited to, chimeric antigen receptors (CARs)
and variants thereof, Immunotoxins, and
antibody-drug conjugates (ADCs).
The present inventions to be licensed
concern monoclonal antibodies that are
specific for the cell surface domain of
GPC3: YP6, YP7, YP8, YP9 and YP9.1.
These antibodies can potentially be
used for the treatment of GPC3expressing cancers such as HCC. By
binding to and blocking GPC3 function,
these antibodies can inhibit the growth
of HCC cells, thereby decreasing the
ability of tumors to grow and
metastasize. Alternatively, the
antibodies can be used to induce
antibody-dependent anti-tumor activity
by selectively killing cells which
overexpress GPC3 while leaving
healthy, normal cells unscathed.
Finally, a secondary antibody capable of
recruiting T cells to the tumor can be
attached to the antibodies, thereby
allowing for the localization of T cells
or NK cells only to those cells which
express GPC3, similarly leading to the
selective killing of the cancer cells.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective Exclusive Patent
License will be royalty bearing and may
be granted unless within fifteen (15)
days from the date of this published
notice, the National Cancer Institute
receives written evidence and argument
that establishes that the grant of the
license would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
E:\FR\FM\19MYN1.SGM
19MYN1
Agencies
[Federal Register Volume 82, Number 96 (Friday, May 19, 2017)]
[Notices]
[Pages 23012-23013]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10153]
[[Page 23012]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Chimeric L1/L2
Protein and Virus-Like Particles Based Human Papillomavirus Vaccines
AGENCY: National Institutes of Health, Department of Health and Human
Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an exclusive patent license to practice the
inventions embodied in the U.S. Patents and Patent Applications listed
in the Supplementary Information section of this notice to PathoVax,
LLC located in Baltimore, MD.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before June 5, 2017 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated exclusive license should be
directed to: Kevin W. Chang, Ph.D., Senior Technology Transfer Manager,
NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-
9702 Telephone: (240)-276-6910; Facsimile: (240)-276-5504 Email:
changke@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
United States Provisional Patent Application No. 60/649,249 filed
February 1, 2005 and entitled, ``Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Cross-neutralizing Antibodies'' [HHS
Reference No. E-103-2005/0-US-01]; United States Provisional Patent
Application No. 60/697,655 filed July 7, 2005 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Reference No. E-103-2005/1-US-01];
United States Provisional Patent Application No. 60/752,268 filed
December 21, 2005 and entitled, ``Papillomavirus L2 N-terminal Peptides
For The Induction Of Broadly Cross-neutralizing Antibodies'' [HHS
Reference No. E-103-2005/2-US-01]; International PCT Application No.
PCT/US2006/003601 filed February 1, 2006, and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Reference No. E-103-2005/3-PCT-
01]; United States Patent No. 8,404,244, issued March 26, 2013 and
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-US-
02]; United States Patent No. 9,388,221 issued July 12, 2016 and
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-US-
10]; Canadian Patent Application No. 2,596,698 filed February 1, 2006
and entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction
Of Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-
CA-03]; Australian Patent No. 2006210792 issued November 8, 2012 and
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-AU-
04]; Japanese Patent No. 5224821 issued March 22, 2013 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-JP-05];
Brazilian Patent Application No. PI0607097-3 filed February 1, 2006 and
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-BR-
06]; Chinese Patent No. 200680011079.1 issued March 27, 2013 and
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-CN-
07]; Indian Patent No. 263255 issued October 16, 2014 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-IN-08];
European Patent No. 1853307 issued December 14, 2016 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-EP-09];
German Patent No. 1853307 issued December 14, 2016 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-DE-11];
French Patent No. 1853307 issued December 14, 2016 and entitled,
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-FR-12]; and
United Kingdom Patent No. 1853307 issued December 14, 2016 and
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-GB-
13]. The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the use of Licensed Patent Rights
for the following: ``Use of Human Papillomavirus Virus (HPV) L1/L2
chimeric proteins and Virus Like Particles (VLPs) for the prevention
and/or treatment of cutaneous, mucosal HPV infections and diseases.''
The subject technologies are papillomavirus L2 capsid protein based
vaccines against HPV. The L2 protein is the minor papillomavirus capsid
protein for papillomaviruses. It is known that antibodies to this
protein can neutralize homologous infection. Furthermore, L2 proteins
can induce cross-neutralizing antibodies. Specifically, epitopes at the
N-terminus of L2 shared by cutaneous and mucosal types of
papillomavirus types and by types that infect divergent species are
broadly cross-neutralizing. These epitopes at the N-terminus of L2 can
be used to elicit cross-neutralizing antibodies against different types
of HPV.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Exclusive Patent License Agreement.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
[[Page 23013]]
Dated: May 11, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2017-10153 Filed 5-18-17; 8:45 am]
BILLING CODE 4140-01-P